CHARLES SCHWAB INVESTMENT MANAGEMENT INC - ADVERUM BIOTECHNOLOGIES INC ownership

ADVERUM BIOTECHNOLOGIES INC's ticker is ADVM and the CUSIP is 00773U108. A total of 157 filers reported holding ADVERUM BIOTECHNOLOGIES INC in Q4 2020. The put-call ratio across all filers is 1.58 and the average weighting 0.3%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of ADVERUM BIOTECHNOLOGIES INC
ValueSharesWeighting
Q3 2023$54,620
-5.7%
36,4130.0%0.00%
Q2 2023$57,897
+28.3%
36,413
-42.1%
0.00%
Q1 2023$45,135
+23.8%
62,9140.0%0.00%
Q4 2022$36,459
-39.2%
62,9140.0%0.00%
Q3 2022$60,000
-76.7%
62,914
-67.9%
0.00%
Q1 2022$257,000
-32.5%
195,885
-9.4%
0.00%
Q4 2021$381,000
-18.9%
216,1390.0%0.00%
Q3 2021$470,000
-78.2%
216,139
-65.0%
0.00%
-100.0%
Q2 2021$2,160,000
-64.2%
616,913
+0.9%
0.00%
-50.0%
Q1 2021$6,026,000
-6.3%
611,108
+3.0%
0.00%
-33.3%
Q4 2020$6,432,000
+9.0%
593,298
+3.6%
0.00%0.0%
Q3 2020$5,899,000
-37.6%
572,682
+26.6%
0.00%
-40.0%
Q2 2020$9,447,000
+151.0%
452,396
+17.5%
0.01%
+150.0%
Q1 2020$3,763,000
-0.8%
385,156
+16.9%
0.00%0.0%
Q4 2019$3,795,000
+116.5%
329,375
+2.4%
0.00%
+100.0%
Q3 2019$1,753,000
+13.4%
321,599
+147.5%
0.00%0.0%
Q2 2019$1,546,000
+133.9%
129,942
+3.0%
0.00%
Q1 2019$661,000
+84.1%
126,132
+11.0%
0.00%
Q4 2018$359,000
-47.8%
113,6770.0%0.00%
Q3 2018$688,000
+14.1%
113,6770.0%0.00%
Q2 2018$603,000
+683.1%
113,677
+303.0%
0.00%
Q1 2017$77,000
-6.1%
28,2090.0%0.00%
Q4 2016$82,000
-29.3%
28,2090.0%0.00%
Q3 2016$116,000
+28.9%
28,2090.0%0.00%
Q2 2016$90,00028,2090.00%
Other shareholders
ADVERUM BIOTECHNOLOGIES INC shareholders Q4 2020
NameSharesValueWeighting ↓
BML Capital Management, LLC 3,915,000$5,872,5005.39%
Versant Venture Management, LLC 5,068,233$7,602,3504.04%
Sonic GP LLC 2,000,000$3,000,0002.91%
COMMODORE CAPITAL LP 10,000,000$15,000,0001.75%
VR Adviser, LLC 6,573,300$9,859,9501.04%
AIGH Capital Management LLC 1,323,985$1,985,9770.94%
Newtyn Management, LLC 1,025,000$1,537,5000.38%
Worth Venture Partners, LLC 331,668$497,5020.30%
Acuitas Investments, LLC 291,169$436,7540.26%
Quinn Opportunity Partners LLC 398,298$597,4470.08%
View complete list of ADVERUM BIOTECHNOLOGIES INC shareholders